FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105536009> ?p ?o ?g. }

• W2105536009 endingPage "785" @default.
• W2105536009 startingPage "783" @default.
• W2105536009 abstract "Adenosine (ADO) 1 Abbreviations used: ADO: adenosine, fMLP: formyl-methionyl-leucyl-phenylalanine, EC50: concentration required for half maximal effect, PMN: polymorphonuclear leucocyte, DMSO: dimethyl sulfoxide, CPS: counts per second. 1Abbreviations used: ADO: adenosine, fMLP: formyl-methionyl-leucyl-phenylalanine, EC50: concentration required for half maximal effect, PMN: polymorphonuclear leucocyte, DMSO: dimethyl sulfoxide, CPS: counts per second. has a pharmacological profile which makes it an interesting ‘drug’ to handle many of the problems arising with ischemia and reperfusion [for references see 4]. In human blood, however, it is rapidly taken up by the red blood cells and metabolized to inactive inosine and hypoxanthine. This transporter-mediated uptake can be specifically inhibited in vitro by a few drugs, known as nucleoside transport inhibitors. It has been reported that ADO can inhibit platelet aggregation in whole blood in the presence of dipyridamole [2], and it is well-known that ADO can inhibit the respiratory burst of purified neutrophils induced by certain stimuli [1]. We investigated the effect of some of these drugs on the ADO-mediated inhibition of the fMLP-induced respiratory burst in neutrophils (as measured by lucigenin-enhanced luminescence [3]), in undiluted whole blood. The combination of R 75 231 (a newly developed analog of mioflazine, with unique pharmacokinetic properties, for details see [5]) with ADO (0.1 μm) inhibited the luminescence by 40 ± 4% (n = 10), while either R 75 231 or ADO alone did not affect the response to fMLP. In the presence of ADO (1 μm), R 75 231 (EC50 = 1.9 ± 0.3 × 10−7 m) (n = 3) was almost as potent as dilazep (EC50 = 1.1 ± 0.2 × 10−7 m) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 ± 0.2 × 10−6 m) (n = 3). The present data show that ADO can inhibit PMN-activation in whole blood in the presence of R 75 231 or of other nucleoside transport inhibitors. This suggests that ADO, whenever produced locally, as during cardiac ischemia [6], may exert its biological effects in the presence of effective nucleoside transport inhibition." @default.
• W2105536009 created "2016-06-24" @default.
• W2105536009 creator A5013121659 @default.
• W2105536009 date "1991-07-01" @default.
• W2105536009 modified "2023-09-25" @default.
• W2105536009 title "Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence" @default.
• W2105536009 cites W104407421 @default.
• W2105536009 cites W1965321622 @default.
• W2105536009 cites W1983959416 @default.
• W2105536009 cites W2068862347 @default.
• W2105536009 cites W2074475959 @default.
• W2105536009 doi "https://doi.org/10.1016/0022-2828(91)90211-4" @default.
• W2105536009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1791629" @default.
• W2105536009 hasPublicationYear "1991" @default.
• W2105536009 type Work @default.
• W2105536009 sameAs 2105536009 @default.
• W2105536009 citedByCount "8" @default.
• W2105536009 crossrefType "journal-article" @default.
• W2105536009 hasAuthorship W2105536009A5013121659 @default.
• W2105536009 hasConcept C1621761 @default.
• W2105536009 hasConcept C178790620 @default.
• W2105536009 hasConcept C181199279 @default.
• W2105536009 hasConcept C185592680 @default.
• W2105536009 hasConcept C202751555 @default.
• W2105536009 hasConcept C203014093 @default.
• W2105536009 hasConcept C2776543447 @default.
• W2105536009 hasConcept C2776991684 @default.
• W2105536009 hasConcept C2778452553 @default.
• W2105536009 hasConcept C2781116151 @default.
• W2105536009 hasConcept C55493867 @default.
• W2105536009 hasConcept C71924100 @default.
• W2105536009 hasConcept C96529984 @default.
• W2105536009 hasConcept C98274493 @default.
• W2105536009 hasConceptScore W2105536009C1621761 @default.
• W2105536009 hasConceptScore W2105536009C178790620 @default.
• W2105536009 hasConceptScore W2105536009C181199279 @default.
• W2105536009 hasConceptScore W2105536009C185592680 @default.
• W2105536009 hasConceptScore W2105536009C202751555 @default.
• W2105536009 hasConceptScore W2105536009C203014093 @default.
• W2105536009 hasConceptScore W2105536009C2776543447 @default.
• W2105536009 hasConceptScore W2105536009C2776991684 @default.
• W2105536009 hasConceptScore W2105536009C2778452553 @default.
• W2105536009 hasConceptScore W2105536009C2781116151 @default.
• W2105536009 hasConceptScore W2105536009C55493867 @default.
• W2105536009 hasConceptScore W2105536009C71924100 @default.
• W2105536009 hasConceptScore W2105536009C96529984 @default.
• W2105536009 hasConceptScore W2105536009C98274493 @default.
• W2105536009 hasIssue "7" @default.
• W2105536009 hasLocation W21055360091 @default.
• W2105536009 hasLocation W21055360092 @default.
• W2105536009 hasOpenAccess W2105536009 @default.
• W2105536009 hasPrimaryLocation W21055360091 @default.
• W2105536009 hasRelatedWork W1504841080 @default.
• W2105536009 hasRelatedWork W1869455905 @default.
• W2105536009 hasRelatedWork W2003429048 @default.
• W2105536009 hasRelatedWork W2071896195 @default.
• W2105536009 hasRelatedWork W2077617621 @default.
• W2105536009 hasRelatedWork W2087657802 @default.
• W2105536009 hasRelatedWork W2159710370 @default.
• W2105536009 hasRelatedWork W2162250764 @default.
• W2105536009 hasRelatedWork W2335776708 @default.
• W2105536009 hasRelatedWork W2408030517 @default.
• W2105536009 hasVolume "23" @default.
• W2105536009 isParatext "false" @default.
• W2105536009 isRetracted "false" @default.
• W2105536009 magId "2105536009" @default.
• W2105536009 workType "article" @default.